key: cord-0781848-vpm26br9
authors: Cimaglia, Paolo; Tolomeo, Paolo; Rapezzi, Claudio
title: Acute Myocarditis after SARS-CoV-2 Vaccination in a 24-Year-Old Man
date: 2021-07-24
journal: Rev Port Cardiol
DOI: 10.1016/j.repc.2021.07.005
sha: 0c98f9d611cd4f31c1ab43ec6e1a5c90254bd8a5
doc_id: 781848
cord_uid: vpm26br9

nan

Our case describes an episode of acute myocarditis after SARS-CoV-2 vaccination. Notably, it was a "usual" case of myocarditis, with an ACS-like presentation and a favorable course in terms of left ventricle function and arrhythmias. The causal relation between vaccination and myocarditis is strongly supported by their strict temporal relationship.

In general, immunization-related myocarditis is rare and mainly occurs after vaccination against smallpox. Usually, it occurs 10 days after vaccination without life threatening complications. 2, 3 The exact immunological mechanisms linking vaccination and myocarditis are unknown. Experimental evidence suggests that a type III hypersensitivity mediated by immunocomplexes could play a role. 4 Moreover, the activation of the antigen-presenting cells is crucial in preclinical models of myocarditis. In humans, pro-inflammatory triggers such as vaccination or infections can overwhelm the self-tolerance mechanism inducing heart-specific autoimmunity. 5

In conclusion, similar to other types of vaccinations, myocarditis may also occur after administering the vaccine against SARS-CoV-2. Clinicians must be aware of this possible complication, but by no means should this rare adverse event discourage the practice of this essential preventive strategy.

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations

Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine

Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination

Eosinophilic myocarditis in an adolescent: A case report and review of the literature

The authors have no conflicts of interest to declare.